CN105982919A - Biological retarder anti-cancer technology - Google Patents
Biological retarder anti-cancer technology Download PDFInfo
- Publication number
- CN105982919A CN105982919A CN201510088530.0A CN201510088530A CN105982919A CN 105982919 A CN105982919 A CN 105982919A CN 201510088530 A CN201510088530 A CN 201510088530A CN 105982919 A CN105982919 A CN 105982919A
- Authority
- CN
- China
- Prior art keywords
- biological
- moderator
- cancer
- retarder
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
In order to solve the high-speed cancer excited state problem, a biological retarder is needed. Cancer energy is converted into intramolecular transfer or other vibrational state transfer through collision. By means of the nucleus retarder principle, a neutron and a retarder atomic nucleus are subjected to collision so that the speed can be decreased, and the retarder which does not absorb neutrons and does not react with neutrons is selected. An important task of the cancer biology and even the natural science is that which material can bear a cancer nuclear fission biological retarder. According to repeated experiments, various safety factors are synthesized, and finally a biological moderator is correctly selected through a successful experiment. Bifidobacterium is free of toxicity and harm to a body, and the biological retarder can be ideal for treating a cancer. In the future, more microorganism retarders will be produced, the biological retarder is used for decelerating tumors, a proper amount of deceleration molecular nuclear energy can be used as senile cell addition nuclear energy, and the biological retarder gives power to biological science and will play an indispensable critical role.
Description
Technical field
The mankind explore the time that cancer has gone through century more than one, but the lethal challenge of cancer but remains unchanged, and become current natural section highlightedly
Learn great difficult problem.Although cancer problem affects the heart of " millions of people, scientists is also racked one's brains, and manages to disclose its very crux, but for a long time with
Do not obtain essence to break through.Cancer cell dyskaryosis, cell is inmature, anaplastic.High nucleocytoplasmic ratio, the fever phenomenon of unknown cause and uranium
Feature, nucleocytoplasmic ratio during nuclear fission, mass deficit, abnormal huge energy etc., have perfectly in harmony surprising identical.Microcosmic atomic nucleus is anti-
Should be closely bound up with macroscopic material evolutionary process, cancer cell nuclear fission " supernova outburst " nuclear fission famous with nuclear fission phenomenon, universe,
Of an identical nature, it is the physics basic law of coincidence or own profound?Cancer cell nuclear fission is no biological minor matters phenomenon, may be potential natural
Unity of sciences rule.Nuclear division physical image word starts from uranium nuclei the earliest and is broken into two almost equal parts ... this situation with
Biologically the fission process of cell proliferation is closely similar, and this makes us have reason this phenomenon to be referred to as ' nuclear fission ' ".Split by microcosmic uranium nuclei
Change to cosmoscopic neutron star nuclear fission, finally revert to the successful description of molecule cancer cell nuclear fission event.Cancer cell nuclear fission discloses cosmoscopic core deeply
Comprehensive uniformity in biological gene for the synthesis mechanism.Represent on molecular biosciences level again and developed Einstein's mass-energy relation E=mc2.
Cancer is exactly nucleus fission one nuclear physics basic law.
Background technology
Four big spectrum (purple, glimmering, red, Raman) spectrum two-dimensional excitation information confirm;Cancer substance spectra absorption blue-shift shows that the sub-state of cancer amount of DNA has higher
Energy level
Between the extent of polymerization of modern apparent genetics research discovery oncogene and spatial configuration and normal structure, there is significant difference.Cancer cell DNA is purple
Outer line absorption top aspect all compared with normal tissue DNA absworption peaks and trend towards blue-shifted phenomenon, oncogene, cancer RNA, oncoprotein suffers from
Above-mentioned DNA excites molecule blue shift specific phenomenon, and this means that there is quantum specific genetic phenomenon in DNA secondary structure, and this is no minor matters
Phenomenon.And it is finally possible to related with quantum genetics general principle to biological quantum mechanics.The nucleoprotein ultraviolet radiation absorption of oncogene strong bonded is
Peak moves 5-8 millimicron to shortwave aspect, quite mutually with energy be every gram molecule be 2-3 thousand card, similar complex fastness and
Hard-decomposed, oncogene excitation state quantum all depends on this.Cancer cell Embryo, oncogene high polymeric and overall DNA molecular structure with
And DNA excited electronic state is relevant.
In the β decay process of atom, the time of abundance is had to allow unstable nuclear synthesis.Same in the cell differentiation procedure in life very long years, cell
Replicate the homoatomic β decay processes such as differentiation.Having the time of abundance, it is allowed to have unstable nucleus to be polymerized, it is exactly that nucleus closes that cancer is dedifferented
The change procedure becoming.Biological normal cell is one and replicates the stable balance system of differentiation, due to the change of surrounding environment or by extraneous active force
And becoming the cancer cell of nonequilibrium condition, the process that this cell is transitioned into new cell balance state from nonequilibrium condition again is known as canceration, and it is borrowed
The DNA relaxation process releasing energy with continuous duplication.Canceration relaxation process substantially cancer cell is for positive energy exchange and the microcosmic in biosystem
Particle interacts, until reaching the distributed process of stable isotope cell.Cancer cell replicates persistence, it is impossible to controlling.Also it is not just difficult to
Reason with somebody.
Content of the invention
Molecular relaxation is a kind of physical phenomenon, be vibrational excitation molecule can by energy at intramolecular transfer to other vibrational state, or turn to rotational and
Translation energy, or produce fluorescence, or it is converted into translation energy through collision, or pass to another molecule.Molecular relaxation refers to molecule by a kind of excitation state transition
The excitation state relatively low to another energy or the process of ground state.Relaxation has various ways.For example, the molecular energy of electron excitation is relatively big, can be directly by electricity
Sub-excitation state jumps back ground state, produces fluorescence: can be gone to triplet T by singlet state S1, then jump to low state S0 from triplet T, produce phosphorescence simultaneously;
Also can transfer the energy to vibration level in S1 state and rotate level, then with mode anergies such as fluorescence;Also can by collision energy become kinetic energy or
It is transferred to another molecule etc..The molecule of vibrational excitation can by energy at intramolecular transfer to other vibrational state, or turn to rotational and translation energy,
Or generation fluorescence, or it is converted into translation energy through collision, or pass to another molecule etc..Relaxation is not instantaneous i.e. to die, so excitation state has one
Fixed life-span, referred to as relaxation time.The macroscopic law of relaxation process is decided by the character that in system, microcosmic particle interacts.Therefore, cancer base is studied
Because of relaxation phenomena be release cancer DNA excited electronic state, return stablize ground state can not by replicate decay process, and be intended to by intermolecular collision by
DNA energy becomes kinetic energy or is transferred to another molecule, and this is only one of radical cure most effective approach of cancer.
For releasing cancer DNA hydrogen electronics highly excited level, come in the urgent need to a kind of biological moderator of development, by collision, cancer DNA energy is become molecule
It is inside transferred to other vibrational state transfer energy.Use for reference decelerating atoms agent principle;The neutron of these rapid movements must occur core anti-being absorbed by nuclear fuel
Before should slow down movement velocity, usual way is to use moderator, i.e. neutron and the atomic nucleus of moderator collides and make speed reduce, choosing
Select the condition of moderator be neither absorb neutron and also with neutron generation nuclear reaction, they can be heavy water, graphite, carbon dioxide or light-water (i.e.
The very high light water of purity).By numerous experiments, we determine that biological moderator is unlikely to be heavy water, graphite, water, but they must be containing slowly
The proton of change effect is formed, the correct selection of biological moderator of the final Success in Experiment of comprehensive multiple safety factors.
Detailed description of the invention
Which kind of material can undertake cancer cell nuclear fission DNA, the biological moderator task of protein hydrogen electronics high speed excitation state material?This is knubble biological
Learning or even a Materiality problem in natural science being around this problem, first we be the foundation having passed through the theory of knowledge (philosophy of biology);Biological substance
Non-physical material, biological moderator and immaterial heavy water, graphite, water moderator, there is its unique forms though biological but be all physics basic law institute
Can summarize.These understanding let us turn to bioprotein, nucleic acid hydrogen bonds group notice from material moderator, for biological moderator structure
Discovery lay a good foundation then pass through primary fine thalline;Bacteriophage and Escherichia coli set up experiment.Results are to good biological moderator effect.
Natural the showing at 255-256 millimicron of cancer HeLa cell ultraviolet spectrogram absworption peak as embryonic cell.Biological by Escherichia coli
After moderator, HeLa cell revert to normal cell direction, at ultraviolet spectra absworption peak curve 260 millimicrons.Establish biology for oncotherapy
Moderator experimental model.
Current antineoplastic mechanism to Bifidobacterium is it is believed that be mainly by strengthening the immunologic function of host, particularly activating macrophage, NK
Cell and bone-marrow-derived lymphocyte, and promote that these effector cells discharge immunity substance, such as 1L-1, IL-6,1L-12, TNF-Q, IFN
-Y, NO etc., thus play indirectly antitumor action;And also can the apoptosis of direct induced tumor cell.Also scholar is had to test discovery bifid bar
The DNA of bacterium also has antitumor action.Bifidobacterium has as the advantage of oncotherapy carrier, does not produce drug resistance, can successive administration;Without bright
Aobvious toxic and side effect, can be used for the treatment of various entity tumor;Bifidobacterium has the advantages such as targeting is good, toxic and side effect is little, therefore, is a kind of reason
The gene therapy vector thought.But, the research in terms of current Bifidobacterium molecular biology is less, and Bifidobacterium is applied to grinding of therapy of tumor
Study carefully and be still in the starting stage, the security etc. of Bifidobacterium transformant.Some more basic problems not yet really solve.
Bifidobacterium is nontoxic to body, therefore can treat tumour as one preferably biological moderator preparation. make biological deceleration with Bifidobacterium
Agent, in addition to itself antitumor action, provides a new thinking for the treatment of slowing down of the excitation state of tumour, for oncotherapy bring one new
Revolution.After biological moderator experiment, it was demonstrated that Bifidobacterium is ideal biological moderator, process to HeLa cell, breast cancer cell,
It after tumour blood of patients with lung cancer, serum deceleration are processed, all successfully revert to 260,279/252nm normal cell spectral absorbance values direction.
The boundless universe.There is no lack of strange things.Bacterium, to live many seeds of trouble being considered as by people and causing a disease, is but used as cancer cell nuclear fission now and virus is quick
Attenuated vaccine produce biological moderator preparation, e. coli k12, MG1665, engineering bacteria DH5 α and JM109 these will not germ and
The preferably biological moderator such as Bifidobacterium, antitumor, will make them be more widely used in antiviral field.It is expected that in the present
After years in, also will have more microorganism moderator preparation and be born, and will be applied more broadly in medical treatment and the field such as health care.Biological deceleration
Agent can be slowed down for tumour cell, and the appropriate cell nuclear energy slowing down can be used as senile cell and adds nuclear energy, and biological moderator is that life science is further strengthened,
To there is indispensable key effect.
Claims (3)
1. use for reference atomic nucleus moderator principle;For releasing cancer DNA high speed excitation quantum state, come in the urgent need to developing a kind of biological moderator, by collision, cancer DNA excitation state is changed into intramolecular excitation energy and shifts, or to the transfer of other vibrational state energy.Thus a kind of biological moderator principle of development and method.Any this principle of use and method produce biological moderator preparation and its anti-cancer technology.
2. antitumor, e. coli k12, MG1665 in antiviral field, engineering bacteria DH5 α and JM109 these will not germ and Bifidobacterium etc. be preferable biological moderator, also will have more microorganism moderator preparation and be born, this will make them be more widely used.Any to treat neoplastic disease, the biological moderator of production application for the purpose for the treatment of virosis.
3. especially Bifidobacterium is nontoxic to body, and Bifidobacterium has the advantages such as targeting is good, toxic and side effect is little, and therefore, you can be a kind of preferable gene therapy vector.Can be used for the treatment of various entity tumor.But your not handy Bifidobacterium makees biological moderator application;Shift for tumour energy or carry out treatment of slowing down, using Bifidobacterium as biological moderator anti-cancer technology.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510088530.0A CN105982919A (en) | 2015-02-26 | 2015-02-26 | Biological retarder anti-cancer technology |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510088530.0A CN105982919A (en) | 2015-02-26 | 2015-02-26 | Biological retarder anti-cancer technology |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105982919A true CN105982919A (en) | 2016-10-05 |
Family
ID=57037823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510088530.0A Pending CN105982919A (en) | 2015-02-26 | 2015-02-26 | Biological retarder anti-cancer technology |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105982919A (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
CN110361345A (en) * | 2018-04-11 | 2019-10-22 | 魏秋英 | Ultraviolet spectra DNA protein phenotypic analysis instrument |
US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
-
2015
- 2015-02-26 CN CN201510088530.0A patent/CN105982919A/en active Pending
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
US11414463B2 (en) | 2013-04-10 | 2022-08-16 | 4D Pharma Research Limited | Polypeptide and immune modulation |
US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US10973872B2 (en) | 2014-12-23 | 2021-04-13 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11273185B2 (en) | 2015-06-15 | 2022-03-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11040075B2 (en) | 2015-06-15 | 2021-06-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11331352B2 (en) | 2015-06-15 | 2022-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744167B2 (en) | 2015-06-15 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11389493B2 (en) | 2015-06-15 | 2022-07-19 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10780134B2 (en) | 2015-06-15 | 2020-09-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11433106B2 (en) | 2015-06-15 | 2022-09-06 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10864236B2 (en) | 2015-06-15 | 2020-12-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11058732B2 (en) | 2015-11-20 | 2021-07-13 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10960031B2 (en) | 2016-07-13 | 2021-03-30 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10967010B2 (en) | 2016-07-13 | 2021-04-06 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10898526B2 (en) | 2016-12-12 | 2021-01-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10543238B2 (en) | 2016-12-12 | 2020-01-28 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11376284B2 (en) | 2017-05-22 | 2022-07-05 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11382936B2 (en) | 2017-05-22 | 2022-07-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
US11660319B2 (en) | 2017-06-14 | 2023-05-30 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11779613B2 (en) | 2017-06-14 | 2023-10-10 | Cj Bioscience, Inc. | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
CN110361345A (en) * | 2018-04-11 | 2019-10-22 | 魏秋英 | Ultraviolet spectra DNA protein phenotypic analysis instrument |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105982919A (en) | Biological retarder anti-cancer technology | |
Atzeni et al. | Shock ignition of thermonuclear fuel: principles and modelling | |
TWI572389B (en) | Instrument set and system for producing change in medium, system for generating light or curing, radiation-cured or curable article, microwave or rf receptor, and system for treatment or diagnosis | |
Pitkänen | Cold fusion, low energy nuclear reactions, or dark nuclear synthesis | |
CN104321827A (en) | Apparatus and method for generating medical isotopes | |
Soker | The role of jets in exploding supernovae and in shaping their remnants | |
AU2015300961B2 (en) | High efficiency neutron capture products production | |
Abbas et al. | Development of an accelerator driven neutron activator for medical radioisotope production | |
Cheng et al. | Hitherto‐Unexplored Photodynamic Therapy of Ag2S and Enhanced Regulation Based on Polydopamine In Vitro and Vivo | |
Gavrilyuk | Hydrogen energy for beginners | |
Gonzales et al. | Ultra-low fluence rate photodynamic therapy: simulation of light emitted by the Cerenkov effect | |
Hossain et al. | Shallow folding potential for 16O+ 12C elastic scattering | |
US20100268012A1 (en) | Radioprotective materials, methods of transport and utilization thereof, nanoscale-microscale supramagnetic and supraconducting particles, spherical flow dynamics and sonoluminesence | |
Ikeda et al. | Fabrication of high-concentration Cu-doped deuterated targets for fast ignition experiments | |
Jin-Gen et al. | Proton halo or skin in the excited states of light nuclei | |
Kudri︠a︡shov | Radiation Biophysics (Ionizing Radiations) | |
Yao et al. | Isoscaling behavior studied by HIPSE model | |
Reisenegger | Neutron stars and their magnetic fields | |
Bouchet et al. | The use of synchrotrons in SFRT and FLASH therapy | |
Purohit et al. | Boron neutron capture therapy: History and recent advances | |
Meesat et al. | Filamentation of femtosecond laser pulses as a source for radiotherapy | |
Schatz | Anniversaries: 2000 | |
Cai et al. | Endohedral Clusterfullerenes: Future Perspectives | |
Liu et al. | Theoretical study on intramolecular hydrogen transfer involving amino-substituted perylenequinone | |
Lebedev et al. | Structures of Nanodiamonds with Photoactive Modifiers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161005 |
|
RJ01 | Rejection of invention patent application after publication |